Drugs facing NCE-1 in 2027
1. Aemcolo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263120 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(5 months from now) | |
| US8529945 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(5 months from now) | |
| US8741948 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(5 months from now) | |
| US8486446 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 16, 2028 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2018
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
AEMCOLO family patents
2. Agamree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11382922 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Jul, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8334279 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κB for treatment of disease |
May, 2029
(4 years from now) | |
| US10857161 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(4 years from now) | |
| US11833159 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(4 years from now) | |
| US11690853 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
Mar, 2033
(8 years from now) | |
| US11471471 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2028 |
| Orphan Drug Exclusivity(ODE-450) | Oct 26, 2030 |
Drugs and Companies using VAMOROLONE ingredient
NCE-1 date: 27 October, 2027
Market Authorisation Date: 26 October, 2023
Treatment: Treatment of duchenne muscular dystrophy
Dosage: SUSPENSION
More Information on Dosage
AGAMREE family patents
3. Augtyro patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9714258 | BRISTOL | Diaryl macrocycles as modulators of protein kinases |
Jan, 2035
(10 years from now) | |
| US10294242 | BRISTOL | Diaryl macrocycle polymorph |
Jul, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11452725 | BRISTOL | Chiral diaryl macrocycles and uses thereof |
Jul, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
| ODE*(ODE*) | Nov 15, 2030 |
| Orphan Drug Exclusivity(ODE-455) | Nov 15, 2030 |
| Orphan Drug Exclusivity(ODE-483) | Jun 13, 2031 |
| Orphan Drug Exclusivity(ODE-488) | Jun 13, 2031 |
Drugs and Companies using REPOTRECTINIB ingredient
NCE-1 date: 16 November, 2027
Market Authorisation Date: 15 November, 2023
Treatment: Treatment of adult and pediatric patients >12 years with solid tumors and ntrk gene fusion that are locally advanced or metastatic or likely surgically unresectable, and have progressed following trea...
Dosage: CAPSULE
More Information on Dosage
AUGTYRO family patents
4. Brenzavvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8802637 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(3 years from now) | |
| US7838499 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Jan, 2029
(4 years from now) | |
| US10981942 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jun, 2031
(6 years from now) | |
| US8987323 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
May, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8106021 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(3 years from now) | |
| US10533032 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 20 January, 2027
Market Authorisation Date: 20 January, 2023
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
More Information on Dosage
BRENZAVVY family patents
5. Daybue patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11370755 | ACADIA PHARMS INC | Compositions of trofinetide |
Aug, 2040
(15 years from now) | |
| US11827600 | ACADIA PHARMS INC | Crystalline forms of trofinetide |
Jul, 2042
(17 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9212204 | ACADIA PHARMS INC | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
| Orphan Drug Exclusivity(ODE-425) | Mar 10, 2030 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 10 March, 2023
Treatment: Treatment of rett syndrome or a symptom thereof
Dosage: SOLUTION
More Information on Dosage
DAYBUE family patents
6. Epclusa patent expiration
EPCLUSA's oppositions filed in EPO
EPCLUSA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(7 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(7 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(6 years from now) | |
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(8 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(8 years from now) | |
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(8 years from now) | |
| US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
| US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
|
US9757406 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
|
US10086011 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| New Patient Population(NPP) | Mar 19, 2023 |
| New Strength(NS) | Mar 19, 2023 |
| M(M-264) | Jul 14, 2023 |
| M(M-277) | Apr 27, 2025 |
| Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 19 March, 2020
Treatment: For the treatment of hepatitis c
Dosage: TABLET
More Information on Dosage
EPCLUSA family patents
7. Exxua patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7538116 | FABRE KRAMER | Treatment of sexual disorders |
Sep, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2028 |
Drugs and Companies using GEPIRONE HYDROCHLORIDE ingredient
NCE-1 date: 23 September, 2027
Market Authorisation Date: 22 September, 2023
Treatment: Treatment of subjects with major depression with sexual dysfunction caused by either major depression or prior treatments, or treatment of subjects with major depression without the risk of sexual dys...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
EXXUA family patents
8. Fabhalta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9682968 | NOVARTIS | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
Jul, 2034
(9 years from now) | |
| US11603363 | NOVARTIS | Crystalline form of LNP023 |
May, 2041
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10093663 | NOVARTIS | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
Jul, 2034
(9 years from now) | |
| US11723901 | NOVARTIS | Uses of piperidinyl-indole derivatives |
Aug, 2038
(13 years from now) | |
| US11951101 | NOVARTIS | Methods of using factor B inhibitors |
Jul, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-949) | Aug 07, 2027 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2028 |
| Orphan Drug Exclusivity(ODE-456) | Dec 05, 2030 |
Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient
NCE-1 date: 06 December, 2027
Market Authorisation Date: 05 December, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan); Treatment of paroxysmal nocturnal hemoglobinuria (pnh) by administration of 200 mg of iptacopan twice daily
Dosage: CAPSULE
More Information on Dosage
FABHALTA family patents
9. Filspari patent expiration
FILSPARI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993461 | TRAVERE | Method for treating disorders associated with glomerular function |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2028 |
| Orphan Drug Exclusivity(ODE-389) | Feb 17, 2030 |
| Orphan Drug Exclusivity(ODE-493) | Sep 05, 2031 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 17 February, 2027
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk for disease progression
Dosage: TABLET
More Information on Dosage
FILSPARI family patents
10. Filsuvez patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8828444 | CHIESI | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
Jun, 2025
(6 months from now) | |
| US9827214 | CHIESI | Use of an oleogel containing triterpene for healing wounds |
Nov, 2030
(6 years from now) | |
| US9352041 | CHIESI | Use of an oleogel containing triterpene for healing wounds |
Nov, 2030
(6 years from now) | |
| US11266660 | CHIESI | Betulin-containing birch bark extracts and their formulation |
Jan, 2039
(14 years from now) | |
| US11083733 | CHIESI | Betulin-containing birch bark extracts and their formulation |
Jan, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2028 |
| Orphan Drug Exclusivity(ODE-460) | Dec 18, 2030 |
Drugs and Companies using BIRCH TRITERPENES ingredient
NCE-1 date: 19 December, 2027
Market Authorisation Date: 18 December, 2023
Treatment: Use of birch triterpenes for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa
Dosage: GEL
More Information on Dosage
FILSUVEZ family patents
11. Fruzaqla patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7829574 | TAKEDA PHARMS USA | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
May, 2028
(3 years from now) | |
| US10519142 | TAKEDA PHARMS USA | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide |
Sep, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8212033 | TAKEDA PHARMS USA | Use of substituted quinazoline compounds in treating angiogenesis-related diseases |
May, 2028
(3 years from now) | |
| US11046674 | TAKEDA PHARMS USA | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide |
Sep, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2028 |
Drugs and Companies using FRUQUINTINIB ingredient
NCE-1 date: 09 November, 2027
Market Authorisation Date: 08 November, 2023
Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vegf therapy, and, if ras wild-ty...
Dosage: CAPSULE
More Information on Dosage
FRUZAQLA family patents
12. Inpefa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7781577 | LEXICON PHARMS INC | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
May, 2028
(3 years from now) | |
| US8476413 | LEXICON PHARMS INC | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
May, 2028
(3 years from now) | |
| US8217156 | LEXICON PHARMS INC | Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use |
Oct, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2028 |
Drugs and Companies using SOTAGLIFLOZIN ingredient
NCE-1 date: 27 May, 2027
Market Authorisation Date: 26 May, 2023
Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...
Dosage: TABLET
More Information on Dosage
INPEFA family patents
13. Jaypirca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10342780 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(12 years from now) | |
| US10695323 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10918622 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(12 years from now) | |
| US10464905 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
| Orphan Drug Exclusivity(ODE-424) | Jan 27, 2030 |
| Orphan Drug Exclusivity(ODE-451) | Dec 01, 2030 |
Drugs and Companies using PIRTOBRUTINIB ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll) who have received at least two prior lines of therapy, including a btk inhibitor and a bcl-2 inhibitor
Dosage: TABLET
More Information on Dosage
JAYPIRCA family patents
14. Jesduvroq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11643397 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(2 years from now) | |
| US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(4 years from now) | |
| US11117871 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(2 years from now) | |
| US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(2 years from now) | |
| US11649217 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 01 February, 2027
Market Authorisation Date: 01 February, 2023
Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia
Dosage: TABLET
More Information on Dosage
JESDUVROQ family patents
15. Joenja patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8653092 | PHARMING | Tetrahydro-pyrido-pyrimidine derivatives |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 24, 2028 |
| Orphan Drug Exclusivity(ODE-430) | Mar 24, 2030 |
Drugs and Companies using LENIOLISIB PHOSPHATE ingredient
NCE-1 date: 25 March, 2027
Market Authorisation Date: 24 March, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
JOENJA family patents
16. Litfulo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9617258 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12077533 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2028 |
Drugs and Companies using RITLECITINIB TOSYLATE ingredient
NCE-1 date: 24 June, 2027
Market Authorisation Date: 23 June, 2023
Treatment: Method of treating severe alopecia areata in adults and adolescents 12 years and older by administering ritlectinib
Dosage: CAPSULE
More Information on Dosage
LITFULO family patents
17. Mavyret patent expiration
MAVYRET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8648037 | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(7 years from now) | |
| US8937150 | ABBVIE | Anti-viral compounds |
May, 2032
(7 years from now) | |
| USRE48923 | ABBVIE | Crystal forms |
May, 2035
(10 years from now) | |
| US9321807 | ABBVIE | Crystal forms |
Jun, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039754 | ABBVIE | Anti-viral compounds |
Jun, 2030
(5 years from now) | |
| US10028937 | ABBVIE | Anti-viral compounds |
Jun, 2030
(5 years from now) | |
| US9586978 | ABBVIE | Anti-viral compounds |
Nov, 2030
(5 years from now) | |
|
US10039754 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
|
US10028937 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
|
US9586978 (Pediatric) | ABBVIE | Anti-viral compounds |
May, 2031
(6 years from now) | |
|
US8648037 (Pediatric) | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(7 years from now) | |
|
US8937150 (Pediatric) | ABBVIE | Anti-viral compounds |
Nov, 2032
(8 years from now) | |
| US10286029 | ABBVIE | Method for treating HCV |
Mar, 2034
(9 years from now) | |
| US11484534 | ABBVIE | Methods for treating HCV |
Mar, 2034
(9 years from now) | |
|
US10286029 (Pediatric) | ABBVIE | Method for treating HCV |
Sep, 2034
(9 years from now) | |
|
US11484534 (Pediatric) | ABBVIE | Methods for treating HCV |
Sep, 2034
(9 years from now) | |
|
USRE48923 (Pediatric) | ABBVIE | Crystal forms |
Nov, 2035
(10 years from now) | |
|
US9321807 (Pediatric) | ABBVIE | Crystal forms |
Dec, 2035
(11 years from now) | |
| US11246866 | ABBVIE | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(11 years from now) | |
|
US11246866 (Pediatric) | ABBVIE | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-230) | Aug 06, 2021 |
| New Patient Population(NPP) | Apr 30, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
| New Dosing Schedule(D-175) | Sep 26, 2022 |
| M(M-259) | Apr 10, 2023 |
| Orphan Drug Exclusivity(ODE-232) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-233) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 10 June, 2021
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) ge...
Dosage: PELLETS; TABLET
More Information on Dosage
MAVYRET family patents
18. Miebo patent expiration
MIEBO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10449164 | BAUSCH AND LOMB INC | Methods of treating ocular disorders using semifluorinated alkanes |
Sep, 2033
(8 years from now) | |
| US10058615 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(8 years from now) | |
| US10576154 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(8 years from now) | |
| US10369117 | BAUSCH AND LOMB INC | Compositions comprising mixtures of semifluorinated alkanes |
Sep, 2033
(8 years from now) | |
| US11357738 | BAUSCH AND LOMB INC | Semifluorinated compounds and their compositions |
Sep, 2036
(11 years from now) | |
| US10507132 | BAUSCH AND LOMB INC | Topical administration method |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
More Information on Dosage
MIEBO family patents
19. Nuzyra patent expiration
NUZYRA's oppositions filed in EPO
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326696 | PARATEK PHARMS INC | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(1 year, 1 month ago) | |
| US7553828 | PARATEK PHARMS INC | 9-aminomethyl substituted minocycline compounds |
Jun, 2025
(6 months from now) | |
| US8383610 | PARATEK PHARMS INC | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9365500 | PARATEK PHARMS INC | 9-aminomethyl substituted minocycline compounds |
Jun, 2021
(3 years ago) | |
| US10124014 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(4 years from now) | |
| US9724358 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(4 years from now) | |
| US9265740 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(4 years from now) | |
| US9314475 | PARATEK PHARMS INC | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(6 years from now) | |
| US10111890 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(12 years from now) | |
| US10383884 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(12 years from now) | |
| US10835542 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of bacterial skin and skin structure infections; Treatment of bacterial skin and skin structure infection; Treatment of subjects having bacterial skin or skin structure infection; Treatment ...
Dosage: TABLET; POWDER
More Information on Dosage
NUZYRA family patents
20. Ogsiveo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951958 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Mar, 2025
(3 months from now) | |
| US7795447 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Aug, 2025
(8 months from now) | |
| US7342118 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Aug, 2025
(8 months from now) | |
| US10710966 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(14 years from now) | |
| US11845732 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(14 years from now) | |
| US10590087 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(14 years from now) | |
| US10941118 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11820748 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(14 years from now) | |
| US11905255 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(14 years from now) | |
| US11884635 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(14 years from now) | |
| US11884634 | SPRINGWORKS | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
Aug, 2039
(14 years from now) | |
| US11612588 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(17 years from now) | |
| US11504354 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(17 years from now) | |
| US11844780 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(17 years from now) | |
| US11807611 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(17 years from now) | |
| US11957662 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11951096 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11925620 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12011434 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12011435 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11938116 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11925619 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12036207 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11872211 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 27, 2028 |
| ODE*(ODE*) | Nov 27, 2030 |
| Orphan Drug Exclusivity(ODE-452) | Nov 27, 2030 |
Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient
NCE-1 date: 28 November, 2027
Market Authorisation Date: 27 November, 2023
Treatment: Treatment of adult patients with progressing desmoid tumors
Dosage: TABLET
More Information on Dosage
OGSIVEO family patents
21. Ojjaara patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486941 | GLAXOSMITHKLINE | Phenyl amino pyrimidine compounds and uses thereof |
Jan, 2030
(5 years from now) | |
| USRE48285 | GLAXOSMITHKLINE | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
Jun, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9809559 | GLAXOSMITHKLINE | (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
Jun, 2035
(10 years from now) | |
| US11963962 | GLAXOSMITHKLINE | Platelet count-agnostic methods of treating myelofibrosis |
Dec, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2028 |
| Orphan Drug Exclusivity(ODE-441) | Sep 15, 2030 |
Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 16 September, 2027
Market Authorisation Date: 15 September, 2023
Treatment: For the treatment of intermediate or high-risk myelofibrosis; For the treatment of intermediate or high-risk myelofibrosis in subjects having a baseline platelet count of less than 50 billion/l
Dosage: TABLET
More Information on Dosage
OJJAARA family patents
22. Orserdu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399520 | STEMLINE THERAP | Selective estrogen receptor modulator |
Dec, 2024
(a month from now) | |
| US7612114 | STEMLINE THERAP | Selective estrogen receptor modulator |
Aug, 2026
(1 year, 8 months from now) | |
| US10385008 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCL |
Jan, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10071066 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(9 years from now) | |
| US10420734 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(9 years from now) | |
| US11779552 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(9 years from now) | |
| US11819480 | STEMLINE THERAP | Methods for treating cancer |
Nov, 2036
(12 years from now) | |
| US10745343 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCl |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer following at least one line of endocrine therapy; Treatment of an er-positive breast cancer
Dosage: TABLET
More Information on Dosage
ORSERDU family patents
23. Paxlovid (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11351149 | PFIZER | Nitrile-containing antiviral compounds |
Aug, 2041
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541034 | PFIZER | Nitrile-containing antiviral compounds |
Oct, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
Drugs and Companies using NIRMATRELVIR; RITONAVIR ingredient
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: Treatment of mild-to-moderate coronavirus disease 2019 (covid-19) in adults who are at high risk for progression to severe covid-19, including hospitalization or death
Dosage: TABLET
More Information on Dosage
PAXLOVID (COPACKAGED) family patents
24. Posluma patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11413360 | BLUE EARTH | Dual mode radiotracer and—therapeutics |
Nov, 2038
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12036290 | BLUE EARTH | Pharmaceutical formulations |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
Drugs and Companies using FLOTUFOLASTAT F-18 GALLIUM ingredient
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen...
Dosage: SOLUTION
More Information on Dosage
POSLUMA family patents
25. Qalsody patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10385341 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10968453 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(10 years from now) | |
| US10669546 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 25, 2028 |
| Orphan Drug Exclusivity(ODE-432) | Apr 25, 2030 |
Drugs and Companies using TOFERSEN ingredient
NCE-1 date: 26 April, 2027
Market Authorisation Date: 25 April, 2023
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults who have a mutation in the superoxide dismutase 1 (sod1) gene
Dosage: SOLUTION
More Information on Dosage
QALSODY family patents
26. Rivfloza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10351854 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(10 years from now) | |
| US11359203 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(10 years from now) | |
| US10738311 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(10 years from now) | |
| US11053502 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(10 years from now) | |
| US11286488 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(13 years from now) | |
| US11661604 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-443) | Sep 29, 2030 |
Drugs and Companies using NEDOSIRAN SODIUM ingredient
NCE-1 date: 30 September, 2027
Market Authorisation Date: 29 September, 2023
Treatment: Method of treating primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION
More Information on Dosage
RIVFLOZA family patents
27. Skyclarys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9670147 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(4 years from now) | |
| US8124799 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Dec, 2029
(5 years from now) | |
| US9701709 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(8 years from now) | |
| US8993640 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11091430 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
Apr, 2029
(4 years from now) | |
| US11919838 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(4 years from now) | |
| US8440854 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
Apr, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2028 |
| Orphan Drug Exclusivity(ODE-427) | Feb 28, 2030 |
Drugs and Companies using OMAVELOXOLONE ingredient
NCE-1 date: 28 February, 2027
Market Authorisation Date: 28 February, 2023
Treatment: Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older; Method of treating friedrich's ataxia by activating the nrf2 pathway which reduces oxidative stress
Dosage: CAPSULE
More Information on Dosage
SKYCLARYS family patents
28. Sohonos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9314439 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(6 years from now) | |
| US9789074 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(6 years from now) | |
| US10292954 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(6 years from now) | |
| US12023312 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(6 years from now) | |
| US11622959 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(12 years from now) | |
| US10864194 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2028 |
| Orphan Drug Exclusivity(ODE-439) | Aug 16, 2030 |
Drugs and Companies using PALOVAROTENE ingredient
NCE-1 date: 17 August, 2027
Market Authorisation Date: 16 August, 2023
Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva; Reduction of heterotopic ossification in patients with fibrodysplasia ossificans (myositis) pro...
Dosage: CAPSULE
More Information on Dosage
SOHONOS family patents
29. Truqap patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10059714 | ASTRAZENECA | Protein kinase B inhibitors |
Oct, 2028
(3 years from now) | |
| US8101623 | ASTRAZENECA | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor |
Mar, 2030
(5 years from now) | |
| US9487525 | ASTRAZENECA | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8809336 | ASTRAZENECA | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors |
Oct, 2025
(11 months from now) | |
| US9006430 | ASTRAZENECA | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein |
Oct, 2025
(11 months from now) | |
| US11760760 | ASTRAZENECA | Protein kinase B inhibitors |
Oct, 2028
(3 years from now) | |
| US10654855 | ASTRAZENECA | Protein kinase B inhibitors |
Oct, 2028
(3 years from now) | |
| US10039766 | ASTRAZENECA | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2028 |
Drugs and Companies using CAPIVASERTIB ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2023
Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...
Dosage: TABLET
More Information on Dosage
TRUQAP family patents
30. Vanflyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8883783 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(2 years from now) | |
| US7820657 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Sep, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8557810 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(2 years from now) | |
| US9585892 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(2 years from now) | |
| US8129374 | DAIICHI SANKYO INC | Method of using imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(2 years from now) | |
| US8865710 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
Aug, 2029
(4 years from now) | |
| US7968543 | DAIICHI SANKYO INC | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
Aug, 2029
(4 years from now) | |
| US8836218 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Mar, 2030
(5 years from now) | |
| US9555040 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
May, 2030
(5 years from now) | |
| US8357690 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Feb, 2031
(6 years from now) | |
| US9675549 | DAIICHI SANKYO INC | Tablet containing composite with cyclodextrin |
Sep, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
Dosage: TABLET
More Information on Dosage
VANFLYTA family patents
31. Velsipity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580841 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Mar, 2030
(5 years from now) | |
| US11091435 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders |
Jun, 2036
(11 years from now) | |
| US10301262 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
Jun, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9126932 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Jul, 2029
(4 years from now) | |
| US11007175 | PFIZER | Methods of treating conditions related to the S1P1 receptor |
Jan, 2036
(11 years from now) | |
| US10676435 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders |
Jun, 2036
(11 years from now) | |
| US11884626 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
Jun, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2028 |
Drugs and Companies using ETRASIMOD ARGININE ingredient
NCE-1 date: 13 October, 2027
Market Authorisation Date: 12 October, 2023
Treatment: A method for treating ulcerative colitis by administering a therapeutically effective amount of estrasimod arginine; A method for treating ulcerative colitis by administering estrasimod arginine in an...
Dosage: TABLET
More Information on Dosage
VELSIPITY family patents
32. Veozah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8871761 | ASTELLAS | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
Apr, 2031
(6 years from now) | |
| US9422299 | ASTELLAS | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10836768 | ASTELLAS | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(9 years from now) | |
| US9987274 | ASTELLAS | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 12, 2028 |
Drugs and Companies using FEZOLINETANT ingredient
NCE-1 date: 13 May, 2027
Market Authorisation Date: 12 May, 2023
Treatment: Treatment of moderate to severe vasomotor symptoms due with menopause; Treatment of moderate to severe vasometer symptoms due to menopause
Dosage: TABLET
More Information on Dosage
VEOZAH family patents
33. Wainua (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8101743 | ASTRAZENECA AB | Modulation of transthyretin expression |
Apr, 2025
(4 months from now) | |
| US9127276 | ASTRAZENECA AB | Conjugated antisense compounds and their use |
May, 2034
(9 years from now) | |
| US9181549 | ASTRAZENECA AB | Conjugated antisense compounds and their use |
May, 2034
(9 years from now) | |
| US10683499 | ASTRAZENECA AB | Compositions and methods for modulating TTR expression |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2028 |
| Orphan Drug Exclusivity(ODE-461) | Dec 21, 2030 |
Drugs and Companies using EPLONTERSEN SODIUM ingredient
NCE-1 date: 22 December, 2027
Market Authorisation Date: 21 December, 2023
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION
More Information on Dosage
WAINUA (AUTOINJECTOR) family patents
34. Xdemvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383659 | TARSUS | Isoxazoline derivatives as pesticides |
Jan, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690826 | TARSUS | Methods for treating demodex blepharitis using lotilaner formulations |
Dec, 2038
(14 years from now) | |
| US11752137 | TARSUS | Ophthalmic compositions for treating ocular Demodex using lotilaner formulations |
Dec, 2038
(14 years from now) | |
| US11197847 | TARSUS | Isoxazoline parasiticide formulations and methods for treating blepharitis |
Dec, 2038
(14 years from now) | |
| US11690827 | TARSUS | Methods for treating ocular Demodex using lotilaner formulations |
Dec, 2038
(14 years from now) | |
| US10835517 | TARSUS | Methods for treating ocular demodex using isoxazoline parasiticide formulations |
Dec, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2028 |
Drugs and Companies using LOTILANER ingredient
NCE-1 date: 25 July, 2027
Market Authorisation Date: 24 July, 2023
Treatment: Treatment of demodex blepharitis via topical administration to an ocular surface
Dosage: SOLUTION/DROPS
More Information on Dosage
XDEMVY family patents
35. Xerava patent expiration
XERAVA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10961190 | TETRAPHASE PHARMS | Crystalline forms of eravacycline |
Oct, 2037
(12 years from now) | |
| US11578044 | TETRAPHASE PHARMS | Crystalline forms of eravacycline |
Oct, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796245 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Aug, 2029
(4 years from now) | |
| US8906887 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 27, 2028 |
Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient
NCE-1 date: 28 August, 2027
Market Authorisation Date: 27 August, 2018
Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older
Dosage: POWDER
More Information on Dosage
XERAVA family patents
36. Ycanth patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11052064 | VERRICA PHARMS | Compositions, methods and systems for the treatment of cutaneous disorders |
May, 2035
(10 years from now) | |
| US11147790 | VERRICA PHARMS | Treatment of cutaneous disorders |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 21, 2028 |
Drugs and Companies using CANTHARIDIN ingredient
NCE-1 date: 22 July, 2027
Market Authorisation Date: 21 July, 2023
Treatment: Topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older; Topical treatment of skin lesions caused by an infection with molluscum contagiosum in adult and pe...
Dosage: SOLUTION
More Information on Dosage
YCANTH family patents
37. Zavzpret patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(9 months ago) | |
| US8481546 | PFIZER | CGRP receptor antagonist |
Oct, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7314883 | PFIZER | Anti-migraine treatments |
Dec, 2023
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 09, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2027
Market Authorisation Date: 09 March, 2023
Treatment: Administration of zavegepant for acute treatment of migraine with or without aura
Dosage: SPRAY, METERED
More Information on Dosage
ZAVZPRET family patents
38. Zemdri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(4 years from now) | |
| US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(4 years from now) | |
| US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 26 June, 2027
Market Authorisation Date: 25 June, 2018
Treatment: Method of using plazomicin to treat bacterial infections
Dosage: SOLUTION
More Information on Dosage
ZEMDRI family patents
39. Zilbrysq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11014965 | UCB INC | Modulation of complement activity |
Jun, 2035
(10 years from now) | |
| US10435438 | UCB INC | Modulation of complement activity |
Jun, 2035
(10 years from now) | |
| US10208089 | UCB INC | Modulation of complement activity |
Jun, 2035
(10 years from now) | |
| US10106579 | UCB INC | Modulation of complement activity |
Jun, 2035
(10 years from now) | |
| US10562934 | UCB INC | Modulation of complement activity |
Jun, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835574 | UCB INC | Modulators of complement activity |
Jun, 2035
(10 years from now) | |
| US11752190 | UCB INC | Modulators of complement activity |
Jun, 2035
(10 years from now) | |
| US11535650 | UCB INC | Modulation of complement activity |
Jun, 2035
(10 years from now) | |
| US11965040 | UCB INC | Modulation of complement activity |
Jun, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 17, 2028 |
| Orphan Drug Exclusivity(ODE-446) | Oct 17, 2030 |
Drugs and Companies using ZILUCOPLAN SODIUM ingredient
NCE-1 date: 18 October, 2027
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of generalized myasthenia gravis (gmg) in an adult patient who is anti-acetylcholine receptor (achr) antibody positive by subcutaneous administration of c5 complement inhibitor zilucoplan
Dosage: SOLUTION
More Information on Dosage
ZILBRYSQ family patents
40. Zurzuvae patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512165 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
| US11236121 | BIOGEN INC | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid |
Aug, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342810 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
| US10172871 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
| US11884696 | BIOGEN INC | Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2028 |
Drugs and Companies using ZURANOLONE ingredient
NCE-1 date: 01 November, 2027
Market Authorisation Date: 31 October, 2023
Treatment: Method of treating postpartum depression
Dosage: CAPSULE
More Information on Dosage
ZURZUVAE family patents